Life Sciences - Invest in Hamilton

Canadian government partners with OmniaBio to expand Hamilton facility for revolutionary cell and gene therapies

The Government of Canada announced Monday (March 24, 2025) that it will work with OmniaBio to expand its facility at McMaster Innovation Park. This expansion aims to manufacture cell and gene therapies and provide production services to companies globally, strengthening Canada’s participation in global…

OmniaBio launches Canada’s largest cell and gene therapy manufacturing facility in Hamilton

OmniaBio Inc. officially opened the doors to its new North American cell and gene therapy (CGT) manufacturing and artificial intelligence (AI) centre of excellence. This state-of-the-art facility in Hamilton is currently the largest of its kind in Canada, marking a significant milestone for the…

Hamilton ranked among top-20 Best Canadian Locations to Invest for 2024

Site Selection Magazine has again recognized Hamilton as one of Canada’s Best Locations to Invest. This underscores Hamilton’s growing reputation as a prime destination for businesses seeking growth and opportunity. Hamilton’s Economic Development Office is pivotal in attracting and supporting businesses looking to establish…

Hamilton: Canada’s rising life sciences powerhouse

Hamilton is rapidly emerging as a major hub for life sciences innovation in Canada, largely driven by McMaster University’s research, innovation, and entrepreneurial support. McMaster has spawned numerous successful startups, like Fusion Pharmaceuticals, which was recently acquired by AstraZeneca for $2.4 billion. Meanwhile, Hamilton…

McMaster-led study to revolutionize cancer care backed by $4.9M Pfizer investment

A groundbreaking study led by McMaster University, aimed at transforming how Canadians with multiple myeloma receive treatment, has secured a $4.9 million investment from Pfizer. The EMBRACE study, coordinated through the Ontario Clinical Oncology Group, will focus on enabling adult patients with relapsed or…

Hamilton’s McMaster and University of Ottawa receive over $115 million to bolster pandemic preparedness

The Canadian Pandemic Preparedness Hub (CP2H), a collaborative effort led by Hamilton’s McMaster University and the University of Ottawa, has secured more than $115 million in research and infrastructure funding. This significant investment by the Government of Canada aims to enhance Canada’s ability to…

Pfizer Canada invests $500,000 in McMaster’s inclusive vaccine research

Pfizer Canada is investing $500,000 in McMaster projects to address critical gaps in health equity during vaccine development and delivery. This investment, announced at McMaster University on Apr. 23, 2024, aims to support the university’s commitment to inclusive excellence in research. Specifically, it will…

McMaster University and King’s College London partner to advance nuclear medicine research and training

In a groundbreaking collaboration, McMaster University and King’s College London’s School of Biomedical Engineering and Imaging Sciences (BMEIS) have joined forces to propel nuclear medicine research and education. Announced on Apr. 8. 2024, these world-leading nuclear research institutions are pooling their expertise to optimize…

Hamilton’s Innovation Factory and Haltech join forces to supercharge Southwestern Ontario innovation

Ontario’s innovation scene is about to get a major boost. Two of the region’s leading hubs, Innovation Factory and Haltech, announced their amalgamation — signifying a renewed commitment to fostering technological innovation, entrepreneurship, and sustainable economic growth across southwestern Ontario. The merger, effective Apr.…

AstraZeneca’s $2.4B acquisition of Fusion Pharmaceuticals marks milestone in cancer treatment

A McMaster University spin-out company, Fusion Pharmaceuticals, is being acquired by pharmaceutical giant AstraZeneca for $2.4 billion. Fusion, founded by McMaster professor John Valliant, develops radioconjugates for precision cancer treatment. By the second quarter of this year, the company will become a wholly-owned subsidiary…

Hamilton named 2023 prime investment destination by Site Selection Magazine

Once again, Hamilton has been listed as a prime investment destination by Site Selection Magazine. In its annual Canada’s Best Locations 2023 report, Site Selection Magazine specifically lauded the Bayfront Industrial Area Strategy, which will assist in creating nearly 4,000 acres of mixed industrial…

AtomVie Global Radiopharma Inc. expands its radiopharmaceutical footprint in Hamilton

The City of Hamilton welcomes another investment to the Airport Employment Growth District! AtomVie Global Radiopharma Inc. (AtomVie), a global leader in the manufacturing and distribution of finished-dose therapeutic radiopharmaceuticals is currently constructing a purpose-built facility for commercial production at 10 Aeropark Blvd. AtomVie…

McMaster Researcher working on cure for Type 1 Diabetes

Canada is already known for the discovery of insulin, but Hamilton-based researcher is looking for a cure. Dr. Harald Stover, a professor at McMaster University and co-founder of Allarta Life Sciences Inc. is working to treat diabetes with a cell-based therapy. This new technology…

Omniabio shares expansion plans with Hamilton investment partners at Collision Conference

Omniabio announced their expansion to the City of Hamilton at the Collision Conference in Toronto, one of the world’s largest tech conferences. Omniabio a subsidiary of CCRM, will be bringing a $580 million, 250,000 sq ft facility into the city as well as 250…

Hamilton’s Life Sciences Sector Grows with Omniabio Biomanufacturing Hub

The Government of Ontario’s support for OmniaBio adds $40 million to the $540 million biomanufacturing project in Hamilton’s life sciences Sector

Hamilton’s Allarta Life Science is Positioned to Revolutionize Diabetes Care

Allarta Life Science explores cell-based therapy as a possible diabetes cure

McMaster Innovation Park Scales-Up to the National Stage

McMaster Innovation Park Scales-up and creates the North America Life Sciences Capital Markets Advisory Council

Hamilton’s Life Sciences Series: In Conversation with Alex Muggah

Synapse Life Science’s Alex Muggah spoke with TheFutureEconomy.ca about Hamilton’s capacity for medical research and innovation.

Hamilton’s Life Sciences Series: In Conversation with Ty Shattuck

McMaster Innovation Park’s Ty J. Shattuck spoke with TheFutureEconomy.ca about talent in Hamilton’s life sciences sector

Hamilton’s Life Sciences Series: In Conversation with Dr. Sheila Singh

Dr. Sheila Singh, Neurosurgeon and Founder of Empirica Therapeutics, speaks with TheFutureEconomy.ca about commercialization and research in Hamilton’s life sciences sector

Hamilton’s Life Sciences Series: In Conversation with Dr. Karen Mossman

Dr. Karen Mossman spoke with TheFutureEconomy.ca about how Hamilton’s collaboration and research partnerships support growth in the life sciences sector.

Hamilton’s Life Sciences: In Conversation with Mayor Fred Eisenberger

Hamilton’s Mayor Fred Eisenberger speaks with TheFutureEconomy.ca about Hamilton’s life sciences sector.

VoxNeuro receives Health Canada II Medical Device designation!

Hamilton’s VoxNeuro has received a Health Canada II Medical Device designation for their Cognitive Health Assessment Management Platform (CHAMP)! The CHAMP Software works with their Cognitive Health Assessment protocol that analyzes the brain’s electro waves to help healthcare providers track cognitive health through aging…

McMaster Innovation Park welcomes a new radiopharmaceutical manufacturing plant!

McMaster University and Fusion Pharmaceuticals are working together to build a radiopharmaceutical manufacturing facility at MIP. The new radiopharmaceutical manufacturing plant will be 27,000 square feet and Good Manufacturing Practice (GMP) certified. It’s a custom built space that will complement ongoing activities for Fusion…

Topic: Life Sciences